Lynparza™ approved in the EU as first-in-class treatment for advanced BRCA-mutated ovarian cancer
AstraZeneca announced that the European Commission (EC) has granted Marketing Authorisation for Lynparza™ (olaparib) capsules (400mg twice daily) as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Legislation & regulation Oncology BRCA-mutated Latest News olaparib ovarian cancer platinum-based chemotherapy Source Type: news
More News: AstraZeneca | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Epithelial Cancer | Marketing | Ovarian Cancer | Ovaries